Mexico Digital Biomarkers Market Analysis

Mexico Digital Biomarkers Market Analysis


$ 3999

Mexico Digital Biomarkers Market was valued at $43.50 Mn in 2023 and is predicted to grow at a CAGR of 22.55% from 2023 to 2030, to $180.59 Mn by 2030. The key drivers of this industry include rising chronic disease burden, increased smartphone penetration, growing focus on preventative care, and government initiatives. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.

ID: IN10MXDH158 CATEGORY: Digital Health GEOGRAPHY: Mexico AUTHOR: Sarita Yadav

Buy Now

Mexico Digital Biomarkers Market Executive Summary

Mexico Digital Biomarkers Market was valued at $43.50 Mn in 2023 and is predicted to grow at a CAGR of 22.55% from 2023 to 2030, to $180.59 Mn by 2030. 

Digital biomarkers are quantifiable physiological and behavioral data collected by digital devices like wearables and smartphones. They provide insights into health, including disease progression and treatment response, enabling continuous monitoring and real-time data collection. These biomarkers are used for various health conditions, such as diabetes, cardiovascular disorders, mental health issues, and neurodegenerative diseases. By tracking metrics like physical activity, heart rate, and sleep patterns, digital biomarkers help clinicians make informed decisions and support research with real-world evidence. As technology advances, their potential to transform healthcare and improve patient outcomes grows.

Chronic diseases are the leading cause of death in Mexico, with prevalent conditions including coronary heart disease, diabetes, and stroke. Over 11% of the population had diabetes and more than 64% of adults were overweight or obese in 2020. The WHO noted over 59,000 active clinical trials globally in 2020, underscoring the rising demand for digital biomarkers.

The market therefore is driven by significant factors like rising chronic disease burden, increased smartphone penetration, growing focus on preventative care, and government initiatives. However, data privacy concerns, the digital literacy gap, limited integration with healthcare systems, and high development costs restrict the growth and potential of the market.

Prominent players in this field are ActiGraph LLC which specializes in wearable devices and data analytics for physical activity and sleep monitoring, contributing to clinical research through reliable digital biomarkers. AliveCor Inc. excels in portable ECG monitoring and AI-driven cardiac analysis, enhancing early diagnosis and intervention with FDA-cleared devices like KardiaMobile. Others contributors include Koneksa, and Altoida Inc. among others.

Mexico Digital Biomarkers Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Rising Chronic Disease Burden: Mexico contends with a high burden of chronic diseases: cardiovascular diseases, constitute 23% of all deaths; diabetes affects over 11% of adults; chronic respiratory diseases like COPD are prevalent; and more than 64% of adults are overweight or obese. These conditions underscore the critical role of digital biomarkers in early detection and management, crucial for addressing Mexico's healthcare challenges and driving the market growth.

Increased Smartphone Penetration: Mexico boasts a high smartphone penetration rate, creating a large potential user base for app-based digital biomarker solutions.

Growing Focus on Preventative Care: A growing emphasis on preventative healthcare in Mexico creates demand for digital biomarkers to identify potential health risks before symptoms arise.

Government Initiatives: The Mexican government supports innovation in healthcare. Initiatives promoting digital health solutions indirectly benefit the digital biomarkers market.

Market Restraints

Data Privacy Concerns: Data security and privacy are major concerns for many Mexicans. Building trust with users regarding data collection, storage, and usage practices is crucial for market growth.

Digital Literacy Gap: While smartphone penetration is high, a digital literacy gap might exist, hindering the adoption of digital biomarker technologies among certain segments of the population.

Limited Integration with Healthcare Systems: Seamless integration of digital biomarker data with existing healthcare information systems in Mexico is necessary for optimal utilization by healthcare professionals. Currently, this integration might be limited.

High Development Costs: The research and development of digital biomarkers involve significant investment in technology, clinical validation, and regulatory compliance. High costs can be a barrier for small and medium-sized enterprises entering the market.

Regulatory Landscape and Reimbursement Scenario

In Mexico, the regulatory oversight of digital biomarkers is primarily handled by COFEPRIS, focusing on medical device regulations, including those for digital health technologies. While specific guidelines for digital biomarkers are still emerging, they are likely categorized based on their intended function and associated risks in capturing physiological data.

Regarding reimbursement, coverage for digital biomarkers in Mexico is currently limited in both public and private sectors. The Sistema Nacional de Salud (SNS) and Instituto Mexicano del Seguro Social (IMSS) typically do not include reimbursement for these technologies. Private health insurance plans may offer partial coverage for specific digital health solutions incorporating digital biomarkers, but comprehensive reimbursement remains underdeveloped. As regulatory frameworks progress and evidence supporting digital biomarker efficacy grows, there may be potential for expanded reimbursement opportunities in the future, contingent upon further regulatory advancements and market acceptance.

Competitive Landscape

Key Players

Here are some of the major key players in the Mexico Digital Biomarkers Market

  • ActiGraph LLC
  • AliveCor Inc.
  • Koneksa
  • Altoida Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Empatica Inc.
  • Vivo Sense
  • IXICO plc
  • Adherium Limited

1. Executive Summary
1.1 Digital Health Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Digital Health Policy in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Mexico Digital Biomarkers Market Segmentation

By Type

  • Wearable
  • Mobile-based Applications
  • Sensors
  • Others

By Clinical Practice

  • Diagnostic digital biomarkers
  • Monitoring digital biomarkers
  • Predictive and Prognostic digital biomarkers
  • Other's (Safety, Pharmacodynamics/ Response, Susceptibility)

By Therapeutic Area

  • Cardiovascular and metabolic disorders (CVMD)
  • Respiratory disorders
  • Psychiatric disorders
  • Sleep & Movement Disease
  • Neurological disorders
  • Musculoskeletal disorders
  • Others (Diabetes, Pain Management)

By End-Use

  • Healthcare companies
  • Healthcare Providers
  • Payers
  • Others (Patients, caregivers)

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 25 July 2024
Updated by: Ritu Baliya

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up